<p>在最新的季度中，5 位分析师对 OrthoPediatrics（NASDAQ: KIDS）提供了评级，展现出看涨和看跌的不同观点。</p>
<p>下表提供了他们最近评级的快速概览，突显出过去 30 天情绪的变化，并与前几个月进行比较。</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看涨</strong></th>
<th align="right"><strong>稍微看涨</strong></th>
<th align="right"><strong>无所谓</strong></th>
<th align="right"><strong>稍微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>总评级</strong></td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>过去 30 天</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 个月前</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 个月前</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 个月前</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>分析师评估的 12 个月价格目标揭示了进一步的见解，平均目标为 24.2 美元，最高估计为 30.00 美元，最低估计为 20.00 美元。这一上升趋势显而易见，目前的平均值较之前的 22.67 美元的平均价格目标增加了 6.75%。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1772460030_0_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="价格目标图表" width="700" height="500" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1772460030_0_0.png"/></p>
<h2>解读分析师评级：深入分析</h2>
<p>通过对最近分析师行动的深入探索，揭示了 OrthoPediatrics 在金融专家中的地位。以下摘要概述了关键分析师、他们的最新评估以及对评级和价格目标的调整。</p>
<table>
<thead>
<tr>
<th>分析师</th>
<th>分析师公司</th>
<th>采取的行动</th>
<th>评级</th>
<th>当前价格目标</th>
<th>之前价格目标</th>
</tr>
</thead>
<tbody>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>上调</td>
<td>持有</td>
<td>$20.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>上调</td>
<td>买入</td>
<td>$30.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Ryan Zimmerman</td>
<td>BTIG</td>
<td>上调</td>
<td>买入</td>
<td>$24.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Mathew Blackman</td>
<td>TD Cowen</td>
<td>宣布</td>
<td>买入</td>
<td>$23.00</td>
<td>-</td>
</tr>
<tr>
<td>Caitlin Roberts</td>
<td>Canaccord Genuity</td>
<td>宣布</td>
<td>买入</td>
<td>$24.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>关键见解：</h3>
<ul>
<li><strong>采取的行动：</strong> 分析师根据市场条件和公司表现调整他们的建议。无论是 “维持”、“上调” 还是 “下调” 他们的立场，反映了他们对 OrthoPediatrics 近期发展的反应。这些信息提供了分析师对公司当前状态的看法快照。</li>
<li><strong>评级：</strong> 分析师对股票进行定性评估，范围从 “跑赢大盘” 到 “跑输大盘”。这些评级传达了分析师对 OrthoPediatrics 相对于更广泛市场表现的预期。</li>
<li><strong>价格目标：</strong> 分析师预测价格目标的变动，提供对 OrthoPediatrics 未来价值的估计。检查当前和之前的目标提供了分析师不断变化的预期的见解。</li>
</ul>
<p>理解这些分析师评估与关键财务指标的关系，可以为 OrthoPediatrics 的市场地位提供有价值的见解。保持信息灵通，做出经过深思熟虑的决策，参考我们的评级表。</p>
<p>随时了解 OrthoPediatrics 的分析师评级。</p>
<p>如果您对跟踪小型股新闻和表现感兴趣，您可以从这里开始跟踪。</p>
<h2>发现 OrthoPediatrics：更深入的观察</h2>
<p>OrthoPediatrics Corp 是一家医疗设备公司。该公司致力于为儿科骨科市场提供产品。该公司设计、开发和商业化植入物和仪器，以满足外科医生和患者的需求。其产品包括 PediLoc、PediPlates、空心螺钉、PediFlexTM 钉、PediNailTM、PediLoc 胫骨和 ACL 重建系统等。</p>
<h3>深入了解 OrthoPediatrics 的财务状况</h3>
<p><strong>市值视角：</strong> 该公司的市值低于行业平均水平，表明其相较于同行规模较小。这一定位可能受到感知增长潜力或运营规模等因素的影响。</p>
<p><strong>收入增长：</strong> 在过去的 3 个月中，OrthoPediatrics 表现积极，截至 2025 年 9 月 30 日实现了 <strong>12.23%</strong> 的收入增长率。这反映了公司营业收入的显著增加。与医疗保健行业的其他公司相比，该公司的增长率高于同行的平均水平。</p>
<p><strong>净利润率：</strong> OrthoPediatrics 的净利润率低于行业标准，表明在实现强劲盈利能力方面存在困难。净利润率为 <strong>-19.22%</strong>，公司可能在有效控制成本方面面临挑战。</p>
<p><strong>股本回报率（ROE）：</strong> OrthoPediatrics 的 ROE 低于行业平均水平，表明在最大化股本回报方面存在挑战。ROE 为 <strong>-3.34%</strong>，公司可能在实现最佳财务表现方面面临障碍。</p>
<p><strong>资产回报率（ROA）：</strong> OrthoPediatrics 的 ROA 低于行业标准，表明在有效利用资产方面存在困难。ROA 为 <strong>-2.36%</strong>，公司可能在从其资产中获得令人满意的回报方面面临挑战。</p>
<p><strong>债务管理：</strong> OrthoPediatrics 的债务与股本比率低于行业平均水平。比率为 <strong>0.28</strong>，公司较少依赖债务融资，保持了债务与股本之间更健康的平衡，这对投资者来说是一个积极的信号。</p>
<h2>理解分析师评级的相关性</h2>
<p>评级来自分析师，或在银行和金融系统内的专家，他们为特定股票或定义的行业报告（通常每季度一次）。分析师通常从公司电话会议和会议、财务报表以及与重要内部人士的对话中获取信息，以做出决策。</p>
<p>分析师可以通过纳入增长预估、收益和收入等指标的预测来增强他们的评估，为投资者提供额外的指导。重要的是要承认，尽管分析师在股票和行业方面是专家，但他们也是人，在提供见解时会表达自己的观点。</p>
<p>本文由 Benzinga 的自动内容引擎生成，并经过编辑审核。</p>

KIDS

<p>在最新的季度中，5 位分析师对 OrthoPediatrics（NASDAQ:KIDS）给出了混合评级，平均 12 个月目标价为 24.2 美元，较之前的目标价上涨了 6.75%。分析师们提高了他们的评级，其中 Truist Securities 和 Needham 等公司的升级尤为显著。尽管公司收入增长率为 12.23%，但面临着-19.22% 的净利润率和-3.34% 的股本回报率（ROE）等挑战。OrthoPediatrics 维持了 0.28 的较低债务与股本比率，表明其在债务和股本之间保持了更健康的平衡。分析师评级为公司在市场上的地位和未来预期提供了洞察</p>

<p>In the latest quarter, 5 analysts provided ratings for OrthoPediatrics (NASDAQ: KIDS), showcasing a mix of bullish and bearish perspectives.</p>
<div class="lb-trans"><p>在最新的季度中，5 位分析师对 OrthoPediatrics（NASDAQ: KIDS）提供了评级，展现出看涨和看跌的不同观点。</p>
</div><p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<div class="lb-trans"><p>下表提供了他们最近评级的快速概览，突显出过去 30 天情绪的变化，并与前几个月进行比较。</p>
</div><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看涨</strong></th>
<th align="right"><strong>稍微看涨</strong></th>
<th align="right"><strong>无所谓</strong></th>
<th align="right"><strong>稍微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>总评级</strong></td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>过去 30 天</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 个月前</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 个月前</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 个月前</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
</div><p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $24.2, a high estimate of $30.00, and a low estimate of $20.00. This upward trend is evident, with the current average reflecting a 6.75% increase from the previous average price target of $22.67.</p>
<div class="lb-trans"><p>分析师评估的 12 个月价格目标揭示了进一步的见解，平均目标为 24.2 美元，最高估计为 30.00 美元，最低估计为 20.00 美元。这一上升趋势显而易见，目前的平均值较之前的 22.67 美元的平均价格目标增加了 6.75%。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1772460030_0_0.png" alt="price target chart" original-src="https://www.benzinga.com/files/images/story/2026/1772460030_0_0.png"/></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<div class="lb-trans"><h2>解读分析师评级：深入分析</h2>
</div><p>The standing of OrthoPediatrics among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<div class="lb-trans"><p>通过对最近分析师行动的深入探索，揭示了 OrthoPediatrics 在金融专家中的地位。以下摘要概述了关键分析师、他们的最新评估以及对评级和价格目标的调整。</p>
</div><table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$20.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$30.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Ryan Zimmerman</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$24.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Mathew Blackman</td>
<td>TD Cowen</td>
<td>Announces</td>
<td>Buy</td>
<td>$23.00</td>
<td>-</td>
</tr>
<tr>
<td>Caitlin Roberts</td>
<td>Canaccord Genuity</td>
<td>Announces</td>
<td>Buy</td>
<td>$24.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>分析师</th>
<th>分析师公司</th>
<th>采取的行动</th>
<th>评级</th>
<th>当前价格目标</th>
<th>之前价格目标</th>
</tr>
</thead>
<tbody>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>上调</td>
<td>持有</td>
<td>$20.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>上调</td>
<td>买入</td>
<td>$30.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Ryan Zimmerman</td>
<td>BTIG</td>
<td>上调</td>
<td>买入</td>
<td>$24.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Mathew Blackman</td>
<td>TD Cowen</td>
<td>宣布</td>
<td>买入</td>
<td>$23.00</td>
<td>-</td>
</tr>
<tr>
<td>Caitlin Roberts</td>
<td>Canaccord Genuity</td>
<td>宣布</td>
<td>买入</td>
<td>$24.00</td>
<td>-</td>
</tr>
</tbody>
</table>
</div><h3>Key Insights:</h3>
<div class="lb-trans"><h3>关键见解：</h3>
</div><ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to OrthoPediatrics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of OrthoPediatrics compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for OrthoPediatrics's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>采取的行动：</strong> 分析师根据市场条件和公司表现调整他们的建议。无论是 “维持”、“上调” 还是 “下调” 他们的立场，反映了他们对 OrthoPediatrics 近期发展的反应。这些信息提供了分析师对公司当前状态的看法快照。</li>
<li><strong>评级：</strong> 分析师对股票进行定性评估，范围从 “跑赢大盘” 到 “跑输大盘”。这些评级传达了分析师对 OrthoPediatrics 相对于更广泛市场表现的预期。</li>
<li><strong>价格目标：</strong> 分析师预测价格目标的变动，提供对 OrthoPediatrics 未来价值的估计。检查当前和之前的目标提供了分析师不断变化的预期的见解。</li>
</ul>
</div><p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into OrthoPediatrics's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<div class="lb-trans"><p>理解这些分析师评估与关键财务指标的关系，可以为 OrthoPediatrics 的市场地位提供有价值的见解。保持信息灵通，做出经过深思熟虑的决策，参考我们的评级表。</p>
</div><p>Stay up to date on OrthoPediatrics analyst ratings.</p>
<div class="lb-trans"><p>随时了解 OrthoPediatrics 的分析师评级。</p>
</div><p>If you are interested in following small-cap stock news and performance you can start by tracking it here.</p>
<div class="lb-trans"><p>如果您对跟踪小型股新闻和表现感兴趣，您可以从这里开始跟踪。</p>
</div><h2>Discovering OrthoPediatrics: A Closer Look</h2>
<div class="lb-trans"><h2>发现 OrthoPediatrics：更深入的观察</h2>
</div><p>OrthoPediatrics Corp is a medical device company. The company is engaged in providing products to the pediatric orthopedic market. The firm designs develop and commercialize implants and instruments to meet the needs of surgeons and patients. Its products, include PediLoc, PediPlates, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc Tibia and ACL Reconstruction System among others.</p>
<div class="lb-trans"><p>OrthoPediatrics Corp 是一家医疗设备公司。该公司致力于为儿科骨科市场提供产品。该公司设计、开发和商业化植入物和仪器，以满足外科医生和患者的需求。其产品包括 PediLoc、PediPlates、空心螺钉、PediFlexTM 钉、PediNailTM、PediLoc 胫骨和 ACL 重建系统等。</p>
</div><h3>A Deep Dive into OrthoPediatrics's Financials</h3>
<div class="lb-trans"><h3>深入了解 OrthoPediatrics 的财务状况</h3>
</div><p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<div class="lb-trans"><p><strong>市值视角：</strong> 该公司的市值低于行业平均水平，表明其相较于同行规模较小。这一定位可能受到感知增长潜力或运营规模等因素的影响。</p>
</div><p><strong>Revenue Growth:</strong> Over the 3M period, OrthoPediatrics showcased positive performance, achieving a revenue growth rate of <strong>12.23%</strong> as of 30 September, 2025. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.</p>
<div class="lb-trans"><p><strong>收入增长：</strong> 在过去的 3 个月中，OrthoPediatrics 表现积极，截至 2025 年 9 月 30 日实现了 <strong>12.23%</strong> 的收入增长率。这反映了公司营业收入的显著增加。与医疗保健行业的其他公司相比，该公司的增长率高于同行的平均水平。</p>
</div><p><strong>Net Margin:</strong> OrthoPediatrics's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of <strong>-19.22%,</strong> the company may encounter challenges in effective cost control.</p>
<div class="lb-trans"><p><strong>净利润率：</strong> OrthoPediatrics 的净利润率低于行业标准，表明在实现强劲盈利能力方面存在困难。净利润率为 <strong>-19.22%</strong>，公司可能在有效控制成本方面面临挑战。</p>
</div><p><strong>Return on Equity (ROE):</strong> OrthoPediatrics's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>-3.34%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<div class="lb-trans"><p><strong>股本回报率（ROE）：</strong> OrthoPediatrics 的 ROE 低于行业平均水平，表明在最大化股本回报方面存在挑战。ROE 为 <strong>-3.34%</strong>，公司可能在实现最佳财务表现方面面临障碍。</p>
</div><p><strong>Return on Assets (ROA):</strong> OrthoPediatrics's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>-2.36%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<div class="lb-trans"><p><strong>资产回报率（ROA）：</strong> OrthoPediatrics 的 ROA 低于行业标准，表明在有效利用资产方面存在困难。ROA 为 <strong>-2.36%</strong>，公司可能在从其资产中获得令人满意的回报方面面临挑战。</p>
</div><p><strong>Debt Management:</strong> OrthoPediatrics's debt-to-equity ratio is below the industry average. With a ratio of <strong>0.28</strong>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<div class="lb-trans"><p><strong>债务管理：</strong> OrthoPediatrics 的债务与股本比率低于行业平均水平。比率为 <strong>0.28</strong>，公司较少依赖债务融资，保持了债务与股本之间更健康的平衡，这对投资者来说是一个积极的信号。</p>
</div><h2>Understanding the Relevance of Analyst Ratings</h2>
<div class="lb-trans"><h2>理解分析师评级的相关性</h2>
</div><p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<div class="lb-trans"><p>评级来自分析师，或在银行和金融系统内的专家，他们为特定股票或定义的行业报告（通常每季度一次）。分析师通常从公司电话会议和会议、财务报表以及与重要内部人士的对话中获取信息，以做出决策。</p>
</div><p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<div class="lb-trans"><p>分析师可以通过纳入增长预估、收益和收入等指标的预测来增强他们的评估，为投资者提供额外的指导。重要的是要承认，尽管分析师在股票和行业方面是专家，但他们也是人，在提供见解时会表达自己的观点。</p>
</div><p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>
<div class="lb-trans"><p>本文由 Benzinga 的自动内容引擎生成，并经过编辑审核。</p>
</div>

超越数字：5 位分析师讨论 Orthopediatrics 的股票